Press Releases
April 9, 2025
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
April 4, 2025
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
March 14, 2025
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
February 14, 2025
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
February 5, 2025
NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization
January 21, 2025
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
December 6, 2024
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
November 27, 2024
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 13, 2024
